fbpx

U.S. Anti-Doping Agency (USADA)

Click here to log in to the
Athlete Connect application

Click here to log in to
Athlete Express

USADA logo with registered symbol.

Global DRO logo in whiteSearch Medications & Ingredients

Search
Search
Close this search box.

Two athletes competing in taekwondoUSADA announced today that Talina Le, of Miami, Fla., an athlete in the sport of taekwondo, has accepted an 18-month sanction after testing positive for a prohibited substance.

Le, 26, tested positive for higenamine as the result of an out-of-competition urine sample she provided on March 27, 2019. Higenamine is a Specified Substance in the class of Beta-2 Agonists and is prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic and Paralympic Committee National Anti-Doping Policies, and the World Taekwondo Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.

Following an investigation into the circumstances of Le’s case, USADA concluded that her positive test was caused by her use of a dietary supplement that listed a prohibited substance on the label. The product has since been added to the High Risk List maintained on USADA’s online dietary supplement safety education and awareness resource – Supplement 411 (www.Supplement411.org). Athletes and other sport stakeholders are reminded that dietary supplements sold in the U.S. do not receive any pre-market safety or efficacy reviews by government authorities, and thus, an increased level of due diligence is necessary to challenge the reasons for use and understand the risks of a positive anti-doping test and/or an adverse health event.

USADA determined that a reduced sanction was appropriate due to Le’s forthright declaration of the supplement on her doping control form and cooperation throughout the results management process. Le’s 18-month period of ineligibility began on March 27, 2019, the date her positive sample was collected. In addition, Le has been disqualified from competitive results obtained on and subsequent to March 27, 2019, including forfeiture of any medals, points and prizes.

In an effort to aid athletes, as well as support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements, as well as performance-enhancing and recreational drugs. If athletes choose to use supplements despite the known risks, USADA has always recommended that athletes use only dietary supplements that have been certified by a third-party program that tests for substances prohibited in sport. USADA currently recognizes NSF Certified for Sport® as the program best suited for athletes to reduce the risk from supplements.

In addition, USADA manages a drug reference hotline, Global Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and distributes a multitude of educational materials, such as an easy-reference wallet card with examples of prohibited and permitted substances, a supplement guide, a nutrition guide, an athlete handbook, and periodic alerts and advisories.

Along with education and testing, robust anti-doping programs enable investigations stemming from tips and whistleblowers. USADA makes available a number of ways to report the abuse of performance-enhancing drugs in sport in an effort to protect clean athletes and promote clean competition. Any tip can be reported using the USADA Play Clean Tip Center, by email at playclean@usada.org, by phone at 1-877-Play Clean (1-877-752-9253) or by mail.

USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.


For more information or media inquiries, click here.